alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

                     The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial                           ( print page 4883)                        property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.                

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel, NIAID Clinical Trials.                    

*Date:*                         February 15, 2008.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hilton Washington/Rockville, Double Tree Name Changed, 1750 Rockville Pike, Rockville, MD 20852.                    

*Contact Person:*                         Barney Duane Price, PhD, Scientific Review Program, DHHS/NIH/NIAID/DEA, Room 3139, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892, (301) 451-2592,                         *pricebd@niaid, nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS).

Dated: January 17, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 08-308  Filed 1-25-08; 8:45 am]

BILLING CODE 4140-01-M
Special Exposure Cohort 

Updates

LaVon B. Rutherford, CHP

NIOSH

Division of Compensation Analysis and Support

July 2014

Idaho Falls, ID 
Purpose

 Update the Advisory Board

 Special Exposure Cohort (SEC) summary 

 Petitions currently under Board review

 Potential SEC petitions (83.14)

 Provide updates for future Board work group 

sessions and meeting preparations 
SEC Summary Table

(as of July 21, 2014)

 Petitions received 219

 Petitions in qualification process 3 

 Petitions qualified for evaluation 131

• NIOSH evaluation in progress 0

• NIOSH evaluation completed 130

– SEC Evaluation Reports 

 with the Advisory Board 

 for recommendation 11 

 Petitions not qualifying for evaluation 85

Note: Petitions not qualifying include five petitions received prior to the 

rule becoming final and Petition 34 where the site was de-listed. 
Petitions in Qualification

• SEC-0216, DOW Chemical Company, Walnut 

Creek, CA (1947-1957)

• SEC-0217, Westinghouse Electric Corp., 

Bloomfield, NJ (1950-2001, Residual Period)

• SEC-0219, Idaho National Laboratory, 

Scoville, ID (1949-1970)
Currently under Board Review 

 Awaiting initial Board action

• SEC-0210, Kansas City Plant
Sites with remaining evaluation periods awaiting action

Fernald 

(SEC-0046)

1984-1989 Sandia National Laboratories -

Albuquerque 

(SEC-0188)

1995-2011

Grand Junction 

Operations Office 

(SEC-0175)

1975-2006 Santa Susana Field Laboratory 

(SEC-0093)

1965

Hanford 

(SEC-0057)

1984-1990 Savannah River Site

(SEC-0103)

1973-2007

Los Alamos National 

Laboratory (SEC-0109)

1996-2005 Simonds Saw and Steel Co.

(SEC-0057)

1958-2006

Rocky Flats Plant

(SEC-0192)

1984-1989 St. Louis Airport Storage Site 

(SEC-0050)

1972-1973; 

1984-1998
Potential SEC Petitions (83.14) 

 Sandia National Laboratories – Albuquerque (1945-48)

 Dayton Project Monsanto (modify based on change in 

facility designation)

• Changed to a Department of Energy facility

• Add the 9-month period when operations were being shifted 

from “The Dayton Project” to Mound
Questions?
EXHIBIT 32.01







Certifying Statement of the Chief Executive Officer pursuant to

Section 906 of the Sarbanes-Oxley Act.





In connection with the Quarterly Report of Gold Star Tutoring Services, Inc. (the "Company") on Form 10-Q for the quarterly period ended September30, 2009as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mindy Kline, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.





A signed original of this written statement required by Section 906 has been provided to Gold Star Tutoring Services, Inc. and will be retained by Gold Star Tutoring Services, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.





November 12, 2009



/s/Mindy Kline_____________

Mindy Kline

Chief Executive Officer

Principal Executive Officer
##### 



1.
    
    Appendix A of the Plan is hereby amended and restated in its
entirety and the Appendix A attached hereto is hereby substituted for the
Appendix A previously attached to the Plan.




---



##### 



Appendix A  Schedule of Outside Directors Compensation
 Annual Fees (1):
    
    Outside Director serving as Chairman of the Board
    
    $
    150,000
    
    Each other Outside Director
    
    $
    65,000
    
    Annual Committee Chair fee:
    
    $
    5,000Meeting Fees (2):
    
    Board meeting fee: (for each meeting attended)
    
    $
    1,250
    
    Committee meeting fee: (for each meeting attended)
    
    $
    1,250Annual Automatic Stock Option Grant:
    
    4,000 stock options
 
 (1)
    
    Payable each Plan Year Quarter in Common Shares unless otherwise elected (cash or stock
options).(2)
    
    Payable only in cash as soon as possible after the end of each Plan Year Quarter. At the beginning of the Fifth Plan Year in May 2003, any eligible Outside Director will be entitled
to receive a one-time grant of an amount of stock options equal to 20% of the Annual Automatic
Stock Options and 15% of the Elective Stock Options he or she has been granted prior to May 6,
2002.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Securities and Exchange Commission

          - [File No. 500-1] 

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Health Professionals, Inc. because it has not filed any periodic reports since it filed a Form 10-Q for the period ended December 31, 1997. 

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company. 

Therefore, it is ordered, pursuant to section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of Health Professionals, Inc. is suspended for the period from 9:30 a.m. EDT on May 5, 2008 through 11:59 p.m. EDT on May 16, 2008. 

By the Commission. 

J. Lynn Taylor, 

 Assistant Secretary. 

[FR Doc. 08-1235 Filed 5-5-08; 11:37am] 

BILLING CODE 8010-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special                               ( print page 7750)                            Emphasis Panel; The Immune Response to Viral Infections in Lymph Nodes.                    

*Date:*                         March 6, 2008.                    

*Time:*                         12 p.m. to 4 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Room 3127, Bethesda, MD 20817, (Telephone Conference Call).                    

*Contact Person:*                         Erica L. Brown, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 301-451-2639,                         *ebrown@niaid.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 4, 2008.

Jennifer Spaeth, 

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 08-578 Filed 2-8-08; 8:45 am]

BILLING CODE 4140-01-M
I 

115TH CONGRESS 

2D SESSION H. R. 5379 

To amend the Food, Agriculture, Conservation, and Trade Act of 1990 

to update the Biotechnology and Agricultural Trade Program, and for 

other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 22, 2018 

Mr. DUNN (for himself and Mr. PANETTA) introduced the following bill; which 

was referred to the Committee on Agriculture 

A BILL 

To amend the Food, Agriculture, Conservation, and Trade 

Act of 1990 to update the Biotechnology and Agricultural Trade Program, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Growing American 

5 Food Exports Act of 2018’’. 


daltland on DSKBBV9HB2PROD with BILLS
2 

•HR 5379 IH

1 SEC. 2. BIOTECHNOLOGY AND AGRICULTURAL TRADE PRO2 GRAM. 

3 Section 1543A of the Food, Agriculture, Conserva4 tion, and Trade Act of 1990 (7 U.S.C. 5679) is amended 

5 to read as follows: 

6 ‘‘SEC. 1543A. BIOTECHNOLOGY AND AGRICULTURAL TRADE 

7 PROGRAM. 

8 ‘‘(a) ESTABLISHMENT.—There is established in the 

9 Department of Agriculture a program to be known as the 

10 ‘Biotechnology and Agricultural Trade Program’. 

11 ‘‘(b) PURPOSE.—The purpose of the program estab12 lished under this section shall be to remove, resolve, or 

13 mitigate significant regulatory nontariff barriers to the ex14 port of United States agricultural commodities into for15 eign markets through policy advocacy and targeted 

16 projects that address— 

17 ‘‘(1) issues relating to United States agricul18 tural commodities produced with the use of new bio19 technology or agricultural production technologies; 

20 ‘‘(2) advocacy for science-based regulation in 

21 foreign markets of new biotechnology or agricultural 

22 production technologies; or 

23 ‘‘(3) quick-response intervention regarding non24 tariff barriers to United States exports produced 

25 through new biotechnology or agricultural produc26 tion technologies. 


daltland on DSKBBV9HB2PROD with BILLS
3 

•HR 5379 IH

1 ‘‘(c) ELIGIBLE PROGRAMS.—Depending on need, as 

2 determined by the Secretary, activities authorized under 

3 this section may be carried out through— 

4 ‘‘(1) this section; 

5 ‘‘(2) the emerging markets program under sec6 tion 1542; or 

7 ‘‘(3) the Cochran Fellowship Program under 

8 section 1543. 

9 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—There 

10 is authorized to be appropriated to carry out this section 

11 $2,000,000 for each of fiscal years 2019 through 2023.’’. 

Æ 


daltland on DSKBBV9HB2PROD with BILLS
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Office of the Secretary

# AGENCY:

Department of Defense.

# ACTION:

 Notice of public meeting.

# SUMMARY:

This notice announces the forthcoming public meeting of the Code Committee established by Article 146(a), Uniform Code of Military Justice, 10 U.S.C. 946(a), to be held at the Courthouse of the United States Court of Appeals for the Armed Forces, 450 E. Street, NW., Washington, DC 20441-0001, at 9 a.m. on Tuesday, March 4, 2008. The agenda for this meeting will include consideration of proposed changes to the Uniform Code of Military Justice and the Manual for Courts-Martial, United States, and other matters relating to the operation of the Uniform Code of Military Justice throughout the Armed Forces.

# FOR FURTHER INFORMATION CONTACT:

William A. DeCicco, Clerk of Court, United States Court of Appeals for the Armed Forces, 450 E Street, NW., Washington, DC 20442-0001, telephone (202) 761-1448.

Dated: January 17, 2008.

C.R. Choate,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 08-291  Filed 1-24-08; 8:45 am]

BILLING CODE 5001-06-M
LAWRENCE BERKELEY

NATIONAL LABORATORY

Update on Work Group 

Activities and

Site Profile Review 
WORK GROUP MEMBERS

• Brad Clawson

• David Richardson

• Paul Ziemer (Chair)
ACTIVITIES RELATING TO LBNL

• Mass records requests and retrievals by NIOSH

• Interviews of some past radiation safety

employees

• Extensive Site Profile related reviews by the

Board’s contractor, SC&A

• Work Group meetings to review NIOSH reports

and SC&A findings 
MEETINGS HELD BY WORK GROUP

• February 3, 2012

• April 5, 2019

• November 25, 2019 
THE LBNL SITE PROFILE

• Initial profile issued August 7, 2006 by NIOSH

• Revision 1 issued April 2, 2007 as a result of

NIOSH internal review

• Revision 2 issued May 19, 2010 following an

SEC petition (SEC 160) 

Note: NIOSH recommended SEC status for 

LBNL for the period August 13, 1942 to 

December 31, 1961. This was approved by the 

Advisory Board March 5, 2010.
REVIEW OF THE SITE PROFILE(S) BY THE 

BOARD’S CONTRACTOR, SC&A 

• 21 Issues:

 13 Findings

 8 Observations

• Some additional Issues have emerged in

connection with the resolution of initial

findings. 

Dr. Megan Lobaugh of NIOSH will summarize the NIOSH 

responses to these issues and give the status of each.
Exhibit 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Wollemi Mining Corp. (the "Company")
on Form 10-Q for the period ending September 30, 2008 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Susana
Gomez, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

IN WITNESS WHEREOF, the undersigned has executed this certification as of the
21st day of October, 2008.


/s/ Susana Gomez
---------------------------
Chief Executive Officer
EXHIBIT 31.02



Certification of Robert M. Kline, Chief Financial Officer, pursuant to

Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended



I, Robert M. Kline, certify that:



1.

I have reviewed this quarterly report on Form 10-Q of Gold Star Tutoring Services, Inc. for the quarterly period ended March 31, 2009;



2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;



(b)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(c)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and



5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and



(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



April 30, 2009

/s/Robert M. Kline__________________

Robert M. Kline, Treasurer

Chief Financial Officer

Principal Accounting and Financial Officer